



CombiGene: Articles about epilepsy and gene therapy

Lacerta Bio, a New York-based business development consultancy, will be writing and publishing a series of articles on epilepsy, gene therapy and related topics. Beginning December 1st, the articles will appear monthly on <http://lacertabio.com/home/epilepsy/>.

The initiative was conceived jointly by Lacerta Bio's Carlos N. Velez and CombiGene's CEO Bengt Westrin during a recent meeting in Copenhagen. Dr. Velez' articles and blogs are distributed to life science business professionals and investors around the world. Bengt Westrin now hopes that these articles will also reach out to CombiGene's shareholders and others that have an interest in these fields. The first article, titled "Epilepsy: An Introduction" is available at <http://lacertabio.com/home/epilepsy/epilepsy-an-introduction/>

"We have realized for a while that CombiGene needed something like this, and I've been on the lookout for someone in Sweden that could do it", he says. "But when meeting Carlos, I realized it didn't have to be a Swede, and it didn't have to be pub-

lished at our own website. I don't think the language will be much of a problem for CombiGene's Swedish followers."

Signing up for Lacerta Bio's newsletters can be made at <http://lacertabio.com>

About Lacerta Bio

Lacerta Bio is a business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities for the pharmaceutical, biotechnology, and drug delivery industries. Lacerta Bio also works with and support internal business development teams with market research, competitive intelligence, financial modeling, and other support services. Lacerta Bio is based in New York. <http://lacertabio.com/>

About CombiGene AB

By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. The current focus is on continuing to develop this method into an effective and safe therapy for epilepsy patients, but the method may also have development potential as a means of treating other neurological disorders. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace AktieTorget. www.combigene.com

For further information:

CombiGene AB (publ)
Bengt Westrin, CEO
Tel: +46 70 – 265 48 62
email: bengt.westrin@combigene.com

MORE FROM THE COMPANY is a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Other issues of MORE FROM THE COMPANY and PRESS RELEASES are available at www.combigene.com

www.combigene.com

CombiGene AB (publ) Medicon Village, SE-223 81 Lund, Sweden
info@combigene.com